Tumour lysis syndrome (TLS)
When a treatment kills so many cancer cells so fast that their contents overwhelm the kidneys and heart. The reason venetoclax starts at a tiny dose and ramps up.
Hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia, and acute kidney injury after rapid cell kill. Risk is highest with bulky CLL and high counts in AML. Venetoclax uses a 5-week ramp-up in CLL (20→400 mg) and a 3-day ramp in AML, with hydration, allopurinol or rasburicase, and monitoring; sonrotoclax uses a 4-week ramp.
Pages like this
not linked directly; found by shared links- IdeaShorter venetoclax courses in unfit AML
Shares VIALE-A, Venetoclax, Acute myeloid leukaemia.
- PairingVenetoclax + obinutuzumab (12 months)
Shares CLL14, Venetoclax, Chronic lymphocytic leukaemia.
- TechnologyBH3 profiling (functional apoptosis testing)
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- PairingVenetoclax + hypomethylating agent
Shares VIALE-A, Venetoclax, Acute myeloid leukaemia.
- TrialCELESTIAL-TNCLL
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia.
- IdeaBTK degraders to pre-empt resistance in frontline CLL
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia.
- IdeaMRD-guided treatment duration in CLL
Shares Sonrotoclax, Venetoclax, Chronic lymphocytic leukaemia.
- PersonAnthony Letai
Shares Venetoclax, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.